Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration

Retina

Volumn 32, Issue 9, 2012, Pages 1804-1810

  Gomi, Fumi ^a   Sawa, Miki ^a   Tsujikawa, Motokazu ^a   Nishida, Kohji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

adjunctive treatment; age related macular degeneration; inflammation; injection frequency; neovascularization; nonsteroidal antiinflammatory drug; ranibizumab

Indexed keywords

ARTIFICIAL TEAR; BROMFENAC; LEVOFLOXACIN; MYTEAR; PLACEBO; RANIBIZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CENTRAL RETINA THICKNESS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INJECTION VOLUME; DRUG WITHDRAWAL; EXUDATIVE MACULAR DEGENERATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTIC DISK; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINA WET AGE RELATED MACULAR DEGENERATION; SHAM PROCEDURE; SIDE EFFECT; THICKNESS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNPLEASANT SENSATION; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZOPHENONES; BROMOBENZENES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84866952500     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31825be87f     Document Type: Article

References (31)

1. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Brown DM, Michels M, Kaiser PK, et al; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
4. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-671.
5. Biarnés M, Monés J, Villalbí JR, Arias L. As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. Eur J Ophthalmol 2011;21: 282-289.
6. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122:598-614.
7. Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets 2009;13:641-651.
8. Grant CA. Combination therapy: Lucentis (ranibizumab injection) and Xibrom (bromfenac ophthalmic solution) 009% in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci 2008;49(suppl). P563.
9. Regillo CD, Brown DM, Abraham P, et al. Randomized, double- masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
10. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010;21:178-183.
11. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006;141: 149-156.
12. Kaiser PK. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007; 23:477-487.
13. Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24:1561-1567.
14. Sakamoto T, Soriana D, Nassaralla J, et al. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1995;113:222-226.
15. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003;44:409-415.
16. Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Arch Ophthalmol 2010;128:596-600.
17. Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 2011;25:127-139.
18. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30:260-266.
19. Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 2008;24:392-398.
20. Yoshinaga N, Arimura N, Otsuka H, et al. NSAIDs Inhibit neovascularization of choroid through HO-1 dependent pathway. Lab Invest 2011;91:1277-1290.
21. Zweifel SA, Engelbert M, Khan S, Freund KB. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009;29:1527-1531.
22. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15-22.
23. Tano Y, Ohji M, EXTEND-I Study Group. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010;88:309-316.
24. Hikichi T, Ohtsuka H, Higuchi M, et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol 2010;150:674-682.
25. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
26. Suzuki M, Gomi F, Sawa M, et al. Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. Jpn J Ophthalmol 2010;54: 124-128.
27. Framme C, Panagakis G, Birngruber R. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51:1671-1676.
28. Flaxel C, Schain MB, Hamon SC, Francis PJ. Prospective randomized trial of combination ranibizumab (lucentis) and bromfenac (xibrom) for neovascular AMD: a pilot study. Retina 2012; 32:417-423.
29. Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea 2006;25:224-227.
30. Bekendam PD, Narváez J, Agarwal M. Case of corneal melting associated with the use of topical nepafenac. Cornea 2007;26: 1002-1003.
31. Gupta B, Adewoyin T, Patel SK, Sivaprasad S. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol 2011; 95:386-390.